Lilly’s Taltz meets primary goal in Phase IV plaque psoriasis trial

Eli Lilly
Lilly’s Taltz meets Phase IV trial’s primary endpoint in patients with moderate to severe plaque psoriasis. Credit: Momoneymoproblemz.